The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'

Alkermes starts phase 1 trial of immuno-oncology drug candidate ALKS 4230.....           FDA advisory committee backs approval of Sanofi treatment for adults with type 2 diabetes.....           Seattle Genetics starts phase 3 trial of vadastuximab talirine for newly diagnosed AML patients.....           Baxalta unveils positive phase 1 results for BAX 930, investigational recombinant ADAMTS13 to treat hTTP.....           Allied-Bristol Life Sciences completes ABLS II drug candidate feasibility programme.....           Serial BioPharma Entrepreneurial Team launches drug development firm Arrivo BioVentures.....           Dr. Reddy?s Laboratories acquires six OTC brands.....           Dr. Reddy?s enters U.S. consumer health market through Ducere Pharma deal.....           Bayer leans on Claritin brand strength for allergy spray launch.....           Don't take migraines lying down, Allergan's new Botox ad urges.....           Novartis would sell its Roche stake without a premium, CEO says.....           Hostile Sanofi puts forth its slate of Medivation directors as Gilead, Celgene weigh their own bids.....           SEC raises red flags over Valeant's 'non-GAAP' measures.....           FDA expands indication for Janssen Pharmaceuticals? Invokamet diabetes drug.....           Cellceutix's phase 2 trial of Prurisol to treat mild to moderate psoriasis meets primary endpoint.....           GSK's Relvar Ellipta succeeds in Salford lung study.....           Eli Lilly says it has potential to launch 20 new products in 10 years.....           FDA committee recommends approval of Novo Nordisk's IDegLira diabetes drug.....           PDL BioPharma commits to equity investment in Noden Pharma.....           Redx Pharma reaches pre-clinical proof of concept stage with oncology lead.....           Allergan continues Viberzi push with online IBS-D awareness tool.....           Irish union balks at Pfizer's proposed pension shake-up.....           Takeda loses again to Hikma in gout drug patent battle.....           Pfizer cancer chief touts up-and-coming portfolio, sees pricing advantage on immunotherapies.....           GSK hopes to keep the Breo train rolling with new real-world COPD data.....           A new day for 'me-too' meds? EU officials say they're tools for holding prices down.....           Embattled Valeant doesn't 'need to sell anything,' new CEO says.....           European Commission approves Darzalex for multiple myeloma.....           Boehringer Ingelheim, BioMed X start project to identify new treatment approaches for psychiatric diseases.....           European Medicines Agency accepts Sandoz' biosimilar rituximab regulatory submission.....           Vtesse completes dose-finding part of phase 2b/3 trial for VTS-270 to treat Niemann-Pick Type C1 disease.....           Exelixis unveils positive results from phase 2 trial of cabozantinib in previously untreated advanced RCC.....           Zambon launches Xadago in UK for patients with mid- to late-stage Parkinson?s Disease.....           FDA to review Samsung Bioepis? BLA for biosimilar of Remicade.....           Sanofi shakes up management as top diabetes exec departs.....           Novartis funds app to boost Xolair in hives.....           Compatriot drugmaker shares Valeant's appetite for price hikes.....           PhIII data puts AZ one step closer to severe-asthma showdown with GSK.....           UPDATED: GSK expects deep discount for Viread in China to boost sales.....           Sanofi shakes up management team as top diabetes exec departs, consumer business expands.....           Note from Stada to activists: We'll replace board members ourselves.....           Novartis gets much-needed boost for Entresto with new heart failure treatment guidelines.....           European regulator accepts Pfizer's Trumenba marketing authorization application for review.....           Acorda to stop Plumiaz development to treat epilepsy seizure clusters.....           Avalon Ventures, COI form PDI Therapeutics to develop novel immune-oncology therapies.....           BioPharma Services wins $20m contract from FDA's Center for Drug Evaluation and Research.....           FDA grants orphan drug designation to ANAVEX 2-73 to treat Rett syndrome.....           Santalis enrolls first patient in phase 2 trial of East Indian Sandalwood Oil to treat mild to moderate plaque psoriasis.....           CoLucid Pharmaceuticals starts second phase 3 trial of lasmiditan in migraine.....           Novartis starts FortiHFy clinical program to study heart failure.....           J&J not ready to throw in the towel in body powder suits.....           Investigators question safety of Pfizer?s Lyrica during pregnancy.....           England stiff-arms Roche again as NICE rejects Perjeta.....           FDA staffers air concerns over Novo's Victoza-Tresiba combo.....           US Senate approves $1.1bn emergency fund to combat Zika virus.....           Merrimack and Baxalta announce initiation of Phase I study of MM-151 in combination with ONIVYDE regimen in metastatic colorectal cancer.....           Celator Pharmaceuticals announces VYXEOS granted breakthrough therapy designation.....           Evoke enters exclusive commercial supply agreement for active pharmaceutical ingredient in EVK-001.....           Inovalon announces agreement with Bristol-Myers Squibb to focus on real world outcomes and value-based contracting initiatives.....           Will Bayer offload animal health to fund its Monsanto bid?.....           Martindale Pharma announces expansion of European commercial activities.....           Novartis stops LEE011 trial due to positive efficacy in HR+/HER2- advanced breast cancer.....           Bristol-Myers Squibb expands Devens biologics facility in Massachusetts.....           JHL Biotech selects PaizaBio to provide fill-finish services for multiple projects.....           Roche's Tecentriq bursts onto immuno-oncology scene, with Merck and BMS in its sights.....           UPDATED: Clock is ticking on CL deal for Novartis' Gleevec, Colombia says.....           Merck's Keytruda shines in pre-ASCO abstract release, with Pfizer catching the limelight, too.....           Amgen researchers discover gene variation that lowers heart attack risk.....           MacroGenics, Janssen partner to develop new DART molecule for cancer treatment.....           FDA approves Genentech's Atezolizumab for advanced urothelial carcinoma.....           EAG unveils further investments to improve ABC Laboratories' biopharmaceutical characterization capabilities.....           RDD Pharma doses first patient in phase 3 trial for chronic anal fissure.....           Synthon starts second part of phase I trial with anti-HER2 antibody-drug conjugate SYD985.....           FDA grants priority review to Genmab's sBLA for ofatumumab in combination with fludarabine and cyclophosphamide in relapsed CLL.....           Mitochon Pharmaceuticals raises $1.6m for clinical stage development.....           Drug price increases lower so far in 2016: Analysts.....           Horizon targets points of care to triumph over generic RA rivals.....           The mano-a-mano between Pfizer's Ibrance and Novartis' LEE011 nears with early PhIII wrap-up.....           AZ's Lynparza misses the mark in gastric cancer trial.....           Valeant weighs sales of controversial heart meds, laggard Provenge: Bloomberg.....           Short-seller Andrew Left puts Mallinckrodt and its Acthar pricing on the spot--again.....           AstraZeneca's benralizumab achieves primary endpoint in two phase 3 asthma trials.....           FDA approves Bristol-Myers Squibb's Opdivo for classical Hodgkin lymphoma.....           Agios, Celgene agree to establish metabolic immuno-oncology alliance.....           Catalyst Pharmaceuticals announces 30% reduction in workforce.....           Bayer, ERS Genomics sign licensing deal for genome editing patents.....           EC grants marketing authorization for Actelion's Uptravi to treat pulmonary arterial hypertension.....           Can Adempas meet Bayer's growth expectations after a canceled trial?.....           Neos Therapeutics launches Adzenys XR-ODT in US to treat ADHD in patients six years and older.....           McKesson and Walmart sign sourcing deal for generic pharmaceuticals.....           Valeant shells out $10.8M in bonuses to keep three top execs.....           Glaxo's Bexsero supply rebounds after demand for MenB jab outstrips supply.....           AstraZeneca cuts 1,600 contract reps, in-house force in drive to save $1.1B: sources.....           'Cornerstone' patent on AbbVie's Humira comes under PTAB review.....           Novartis divides pharma unit in two as division chief Epstein makes an exit.....           Pfizer to buy Anacor Pharmaceuticals in $5.2bn deal.....           Pfizer to buy Anacor Pharmaceuticals in $5.2bn deal.....           Pfizer to buy Anacor Pharmaceuticals in $5.2bn deal.....           Trevena's TRV027 heart failure candidate fails to meet primary, secondary endpoints in phase 2 trial.....           Trevena's TRV027 heart failure candidate fails to meet primary, secondary endpoints in phase 2 trial.....           Trevena's TRV027 heart failure candidate fails to meet primary, secondary endpoints in phase 2 trial.....           AHF urges Congress to authorize funding for Zika virus.....           AHF urges Congress to authorize funding for Zika virus.....           AHF urges Congress to authorize funding for Zika virus.....           Nivalis Therapeutics doses first patient in second phase 2 study of N91115 to treat cystic fibrosis.....           Nivalis Therapeutics doses first patient in second phase 2 study of N91115 to treat cystic fibrosis.....           Nivalis Therapeutics doses first patient in second phase 2 study of N91115 to treat cystic fibrosis.....           Sanofi Genzyme forms multiple sclerosis research collaboration with Johns Hopkins School of Medicine.....           Sanofi Genzyme forms multiple sclerosis research collaboration with Johns Hopkins School of Medicine.....           Sanofi Genzyme forms multiple sclerosis research collaboration with Johns Hopkins School of Medicine.....           Biogen collaborates with University of Pennsylvania on multiple gene therapy programs.....           Biogen collaborates with University of Pennsylvania on multiple gene therapy programs.....           Biogen collaborates with University of Pennsylvania on multiple gene therapy programs.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.

We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.
Forthcoming meeting

APS Excipients - selection, control, application and suitability
23 & 24 May 2016 - Loughborough

This two day residential meeting focusses on pharmaceutical excipients and the current regulatory environment. The meeting will be held on Monday 23rd and Tuesday 24th May 2016 at Burleigh Court, Loughborough, Leicestershire and is organised by the Academy of Pharmaceutical Sciences Material Science and Regulatory focus groups.

There is an offer for group bookings for this event. A 20% discount will be applied to the second and subsequent registrations in a group booking. This is the ideal way to facilitate learning and generate new ideas within the whole team. For more information and to register click here.

Latest News
APS and RPS Awards Announcement
APS Innovative Science Award Lecture 2016. The Academy of Pharmaceutical Sciences present the Innovative Science Award and invite pharmaceutical scientists to submit an application. Entrants are welcome from researchers from across the globe in academia, industry, public service or other scientific establishments. The individual applicant should have demonstrated, through published work, a significant innovation which has the potential for application within the pharmaceutical industry. Prize The winner will receive a Commemorative Award, £1,000 in prize money and an invitation to present the Innovative Science Award Lecture on their work at APS PharmSci 2016. Submission Criteria Applicants are requested to submit their CV and a synopsis of their research of not more than 500 words, focussing on its importance to the pharmaceutical industry. Entries should be submitted via email to Alan Ramsay at including ‘Innovative Science Award 2016’ in the subject field. Your email application must include your full name and postal address, a contact telephone number, your email, and your institution or organisation’s name. Entries will be judged by an APS panel. Closing Date for Entries 31st May 2016. . 2016 Royal Pharmaceutical Society Science Award Applications are invited for the 2016 Royal Pharmaceutical Society Science Award. The winner will receive a Commemorative Award, £1,000 in prize money and an invitation to present the RPS Award Lecture on their work at the 7th Academy of Pharmaceutical Sciences International PharmSci Conference on the 7th September 2016. Applications are welcome from scientists world-wide who are working in a pharmaceutical or allied discipline in industry or academia. With up to 10 years experience at post-doctoral level in September 2016, applicants must have a proven record of independent research and published work that shows outstanding promise. Applicants are invited to submit the following details by 20th May 2016:. Full CV detailing personal information, past and present appointments, research responsibilities and published work. List of research students who have worked for the applicant and their thesis titles and dates, plus any other instances of research collaborations. Details of research grants awarded and the candidate’s role. Invitations to speak at conferences in the UK and overseas, lecture or symposium titles and names of awards. A brief resume of two pages should also be submitted with the CV, indicating discoveries made. Please note copies of publications are not required. Applications should be made by 20th May 2016 preferably by email ( or by post to: Jayne Lawrence, Chief Science Advisor Royal Pharmaceutical Society 66 East Smithfield, London, E1W 1AW.
APS Manufacturing Classification System
TUESDAY, 10 MAY 2016
Be Part of a Successful Global Partnership –APS Manufacturing Classification System . 'Pharmaceutical Sciences: Improving World Health'. Monday 5th – Wednesday 7th September 2016 at the Technology and Innovation Centre, University of Strathclyde, Glasgow. A roundtable session has been organised on Tuesday 6th September at 12.15-13.30, co-chaired by Kendal Pitt (GSK) and Gavin Reynolds (AstraZeneca) giving you the opportunity to input into the Manufacturing Classification System (MCS) and its implementation.. The MCS is a tool for pharmaceutical scientists to rank the feasibility of different processing routes for the manufacture of oral solid dosage forms, based on selected properties of the Active Pharmaceutical Ingredient (API) and the needs of the formulation. The proposed MCS could be used to develop a risk assessment for manufacturing based on "ideal" ranges for API physical properties and therefore indicate how robust a manufacturing process is likely to be in relation to those properties.. This represents a very successful APS-driven Industry collaboration which has already resulted in a publication entitled “‘A proposal for a drug product Manufacturing Classification System (MCS) for oral solid dosage forms”. This was the most downloaded article in Pharmaceutical Development & Technology of 2015 and the cross-industry authors have been commended for their contribution to Pharmaceutical Development & Technology.. For more information and to register for the conference, go to on or before 31st July 2016 to take advantage of the Early Bird Rates for the conference..
APS Alternatives to Antibiotics Meeting
APS Alternatives to Antibiotics Meeting Thursday 16th June 2016 Burleigh Court - Loughborough. Keynote speaker- Dr Lloyd Czeplewski, Chairman of the Wellcome Trust/Department of Health funded review on Alternative to Antibiotics. This one day meeting focussing on exploration of possible opportunities for alternative approaches to traditional antibacterial compounds as potential clinical approaches for treating infectious diseases will be held on Thursday 16th June 2016 at Burleigh Court, Loughborough, Leicestershire ( organised by the APS Microbiology and Anti-infectives Focus Group.. Background to the Meeting:. The withdrawal last Century by the majority of Big Pharma from antibiotic research and development programmes, coupled with other aspects such as a lack of global stewardship over use, has led to the current situation where resistance has left a critical lack of efficacious compounds. The pipeline for development of new antimicrobial agents is critically stagnant and the time to seriously examine viable alternatives for tackling multi-drug resistant pathogens has arrived. The purpose for this meeting will be to allow delegates to hear presentations on a series of alternative approaches including bacteriophage and endolysin therapy, probiotics, antibody technology and immune intervention, which collectively represent the most likely of the alternative approaches to yield genuine clinical impact. Our speakers will highlight the current knowledge base of development in the field in pursuit of discovery of alternatives to antibiotics.. The purpose and aims of the APSGB Microbiology and Anti-Infectives Focus Group is to provide a forum for the discussion of all aspects of microbiology and anti-infectives research and development in the pharmaceutical industry and academia, to underpin the importance of microbiology to the pharmaceutical sciences and innovation, and to provide continuing education, resources and a voice for pharmaceutical scientists in the challenging area of antimicrobials development.. Meeting Format: . We are very pleased to offer a stimulating one day programme of presentations from high profile speakers who are leading experts in their particular fields of research into alternative approaches to traditional small molecule antibiotics, and include representatives of academia, biotechnology SMEs and the pharmaceutical industry.. The Keynote lecture will be delivered by Dr Lloyd Czeplewski, Chairman of the Wellcome Trust/Department of Health funded review on Alternative to Antibiotics, which was published in Lancet Infectious Diseases in January 2016 ( Dr Czeplewski is Founder and Director of Chemical Biology Ventures in and Abgentis, is an international opinion leader and successful scientist entrepreneur in the antibacterial R&D sector. He is currently a champion of the Alternatives to Antibiotics pioneering approaches for treatment of infectious diseases and he will be speaking specifically on this topic.. For more information and registrations, please visit us online at:.
Pharmaceutical Sciences: Improving World Health 7th APS International PharmSci Conference . Monday 5th – Wednesday 7th September 2016 at the Technology and Innovation Centre, University of Strathclyde, Glasgow. How will you benefit from attending this year’s APS International Pharm Sci Conference?. ‘The conference put the icing on the cake. The APS can provide you with these opportunities to make those valuable connections and help you decide if industry is right for you. It’s really helped kick start my career, I can’t urge you enough to get involved and join today!’. Robert Oakley-University of Nottingham – Quote from a Student who attended last year’s conference. Register now to benefit from discounted rates of £66 for one day and up to £170 for three days for at the early bird rate until 31st July 2015. Additional discounts are available for APS members.. What Pharm Sci offers you?. · Opportunity to present your research work via a poster or being selected for a podium presentation. · Network with a broad range of scientists from fellow students to eminent professors from the key UK Universities. · Learn about the latest innovative science by attending a variety of sessions demonstrating how Pharmaceutical Scientists are striving to improve patient health globally · Understand how Pharmaceutical Science is applied in the Industry and what opportunities this might present for you by engaging with representatives from the Pharmaceutical Industry including Pfizer, Astra Zeneca, GSK and BMS.. . Pharm Sci includes:. · A session by the Student Association of the APS (SAPS) on Increasing your employability after your degree. · A session by the APS New Scientist Focus Group offering the opportunity for new scientists to present on Novel Approaches for Improving Health. · View and discuss posters and hear selected abstracts presented at the podium. · Visit the conference exhibition to see and talk to a range of companies offering the latest pharmaceutical science technologies and learn about potential career opportunities.. Book now at to be part of this leading Pharmaceutical Sciences Conference and gain an insight into the opportunities within the Pharmaceutical Sciences..
Follow us
Upcoming Events
APS PharmaFocus Day
June 2016
APS Alternatives to Antibiotics
16 June 2016
CGOM 12 (12th International Workshop of the Crystal Growth of Organic Materials)
26 - 30 June 2016
Symposium of Digital Design of Drug Products - Joint meeting with the British Association of Crystal Growth
1 July 2016
APS Board and Advisory Board Meeting
12 July 2016
Job Vacancies
View all Vacancies
Advertise your job vacancies
Sponsored By
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.


The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351
Fax: 0116 274 7365

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.